This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The biological definition of Parkinson disease (PD) is still an open issue. Indeed, PD represents a heterogeneous disorder in which clinical symptoms may correspond to different biological substrates. In vivo biological characterization of PD is of great importance, to formulate an accurate diagnosis in the early stages of the disease, when clinical symptoms may be uncertain and disease-modifying therapies may have the greatest chance to halt disease progression. In recent years, several advances have been made in the field of fluid biomarkers. Among these, α-synuclein amplification assays (αS-SAAs) in CSF can detect the presence of α-synucleinopathy, the most widely recognized biological feature of PD.1,2 However, αS-SAAs are not yet quantitative, the extracted kinetic features poorly associate with clinical scores, and they do not capture alterations other than α-synucleinopathy that occur in patients with PD (e.g., neuroinflammation, synaptic damage, mitochondrial and autophagic dysfunctions). Moreover, some genetic forms of PD, such as LRKK2-PD, may not be characterized by α-synucleinopathy, and this may explain αS-SAA's poor sensitivity.2
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 606
- Received June 7, 2023.
- Accepted in final form June 14, 2023.
- © 2023 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
